•Multi-nozzle printing system
•Portable and versatile
•In-line quality control measures
•Assured security (fingerprint access, data matrix)
•Suitable for research, drug development and clinical practice
FabRx’s breakthrough 3D printer, M3DIMAKER™, consists of a sleek hardware system that enables printing using different nozzles. The system is controlled by specialised software, allowing the selection of the required dose by the pharmacist according to the prescription given by the clinician. Incorporation of a modern fingerprint access control alongside a data matrix reader ensures manufacturing reliability, as only qualified personnel will have access to the technology’s outstanding features. The system is fitted with advanced in-line quality control procedures alongside camera monitoring of the printing process to track the progress and detect any faults during manufacture.
FabRx’s fused deposition modeling (FDM) 3D printers melt a mixture of drugs and excipients through a nozzle onto a build plate, to construct a dosage form layer-by-layer. FabRx manufactures its own filaments, comprised of pharmaceutical-grade materials, which can be drug-loaded to create sustained or delayed release tablets, as well as multi-drug combinations (polypills).
Direct powder extrusion, a novel 3D printing technology in pharmaceuticals pioneered by FabRx, involves the extrusion of powdered material (a mix of drug and excipients) through a nozzle using a single screw extruder. This technology enables the production of medicines and medical devices in a single-step process to create sustained or delayed release dosage forms.
SLS (or selective laser sintering) printing uses a laser to convert a powder material into solid parts. FabRx can incorporate drugs into the powder to produce drug-loaded printlets with properties ranging from orodispersible through to controlled release characteristics.
SLA (or stereolithography) printing uses a laser to convert liquid material in to solid parts. FabRx can incorporate drugs into the polymer network to produce drug-loaded printlets and sustained release medical devices.
Copyright © 2021 FabRx Ltd